{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-097226","form_type":"8-K","ticker":"TRAW","cik":"0001130598","company_name":"Traws Pharma, Inc.","filed_at":"2026-08-14T20:30:44+00:00","discovered_at":"2026-08-14T20:36:01.490844+00:00","generated_at":"2026-08-14T20:36:26.655433+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Traws Pharma Q2 2026 net loss $3.0M, no revenue; cash $5.0M, runway into Q1 2027","bullets":["Q2 2026 net loss $3.0M ($0.16/share) vs $0.9M loss in Q2 2025; no revenue vs $2.7M prior.","Cash $5.0M at June 30, 2026 vs $3.8M at Dec 31, 2025; expects runway into Q1 2027, may need more financing.","MHRA resubmission for tivoxavir marboxil expected Q3 2026; FDA clinical hold still unresolved, response planned by end 2026.","April 2026 financing delivered $10M upfront, potential $50M via warrants; shareholders approved Series B and C on July 8, 2026.","Six-month net loss $10.2M vs net income $20.6M in 2025 (due to $26.7M warrant gain)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-097226","json":"https://secwatch.observer/filing/0001104659-26-097226.json","markdown":"https://secwatch.observer/filing/0001104659-26-097226.md","text":"https://secwatch.observer/filing/0001104659-26-097226.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130598/000110465926097226/0001104659-26-097226-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130598/000110465926097226/tm2623190d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-14T20:36:26.655433+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}